ijms-logo

Journal Browser

Journal Browser

Cancers across Phylogeny and Cancer Evolution

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 2550

Special Issue Editors

Pathobiology and Extracellular Vesicle Research Group, School of Life Sciences, University of Westminster, London W1W 6UW, UK
Interests: peptidylarginine deiminases; tissue remodelling; extracellular vesicles; CNS regeneration; cancer; mucosal immunity; innate immunity; stem cells
Special Issues, Collections and Topics in MDPI journals
Department of Veterinary Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A&M University, College Station, TX, USA
Interests: Comparative Oncology; cancer immunology; immune contexture, tumour microenvironment; comparative animal models, extracellular vesicles; drug resistance; immune evasion; metastasis; biomarkers; liquid biopsy; osteosarcoma

Special Issue Information

Dear Colleagues,

The fields of comparative cancer research and cancer evolution touch on diverse topics in oncology and are of interest both in human as well as comparative oncology, including through the use of cancer resistant animal models to understand pro- and anti-oncogenic pathways of cancer evolution. Furthermore topics on cancer-host coevolution, transmissible cancers and roles for a range of pathogens including viruses in cancer-host interplay, are an area of increasing exploration.

This Special Issue aims to collect state-of-the-art primary research studies and review articles from international experts and diverse leading groups in the field of cancers in human and across animal species to update our current understanding of cancer diversity (complexity, heterogeneity and interspecies diversity) and cancer evolution. Topics on cancers from human and animal models, cancer evolution, biomarker discovery, as well as diverse roles for viruses and other pathogens, on immunity and infection, in relation to oncology, are welcome.

Dr. Sigrun Lange
Dr. Shay Bracha
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cancer
  • Phylogeny
  • Cancer evolution
  • Cancer resistance
  • Cancer drug resistance
  • Immune evasion
  • Transmissible cancers
  • Coevolution
  • Virus
  • Bacteria
  • Pathology
  • Biomarkers
  • Human cancer
  • Cancer heterogeneity
  • Comparative cancer research
  • Animal models
  • Companion animals
  • Wild animals
  • Cancer metastasis
  • Tumour microenvironment
  • Extracellular vesicles

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

27 pages, 41348 KiB  
Article
A Pilot Study on Peptidylarginine Deiminases and Protein Deimination in Animal Cancers across Vertebrate Species
Int. J. Mol. Sci. 2022, 23(15), 8697; https://doi.org/10.3390/ijms23158697 - 04 Aug 2022
Cited by 1 | Viewed by 1879
Abstract
PADs are a group of calcium-dependent enzymes that play key roles in inflammatory pathologies and have diverse roles in cancers. PADs cause irreversible post-translational modification of arginine to citrulline, leading to changes in protein function in different cellular compartments. PAD isozyme diversity differs [...] Read more.
PADs are a group of calcium-dependent enzymes that play key roles in inflammatory pathologies and have diverse roles in cancers. PADs cause irreversible post-translational modification of arginine to citrulline, leading to changes in protein function in different cellular compartments. PAD isozyme diversity differs throughout phylogeny in chordates, with five PAD isozymes in mammals, three in birds, and one in fish. While the roles for PADs in various human cancers are mounting (both in regards to cancer progression and epigenetic regulation), investigations into animal cancers are scarce. The current pilot-study therefore aimed at assessing PAD isozymes in a range of animal cancers across the phylogeny tree. In addition, the tissue samples were assessed for total protein deimination and histone H3 deimination (CitH3), which is strongly associated with human cancers and also indicative of gene regulatory changes and neutrophil extracellular trap formation (NETosis). Cancers were selected from a range of vertebrate species: horse, cow, reindeer, sheep, pig, dog, cat, rabbit, mink, hamster, parrot, and duck. The cancers chosen included lymphoma, kidney, lung, testicular, neuroendocrine, anaplastic, papilloma, and granulosa cell tumour. Immunohistochemical analysis revealed that CitH3 was strongly detected in all of the cancers assessed, while pan-deimination detection was overall low. Both PAD2 and PAD3 were the most predominantly expressed PADs across all of the cancers assessed, while PAD1, PAD4, and PAD6 were overall expressed at lower, albeit varying, levels. The findings from this pilot study provide novel insights into PAD-mediated roles in different cancers across a range of vertebrate species and may aid in the understanding of cancer heterogeneity and cancer evolution. Full article
(This article belongs to the Special Issue Cancers across Phylogeny and Cancer Evolution)
Show Figures

Figure 1

Back to TopTop